Cantor Fitzgerald Predicts Weaker Earnings for Zai Lab

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) - Equities research analysts at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for Zai Lab in a research note issued on Monday, June 23rd. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will post earnings of ($0.94) per share for the year, down from their prior forecast of ($0.82). Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Zai Lab's current full-year earnings is ($2.58) per share. Cantor Fitzgerald also issued estimates for Zai Lab's FY2026 earnings at $0.27 EPS.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.05. The company had revenue of $106.49 million for the quarter, compared to analysts' expectations of $118.40 million. Zai Lab had a negative return on equity of 33.35% and a negative net margin of 60.26%.

Several other research firms have also recently commented on ZLAB. Scotiabank assumed coverage on Zai Lab in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $55.00 price target on the stock. JPMorgan Chase & Co. boosted their price target on Zai Lab from $44.00 to $51.00 and gave the stock an "overweight" rating in a research note on Thursday, March 13th. Wall Street Zen cut Zai Lab from a "buy" rating to a "hold" rating in a research note on Friday. Finally, Bank of America reiterated a "neutral" rating and issued a $36.10 price target (up previously from $29.00) on shares of Zai Lab in a research note on Monday, March 3rd. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Zai Lab presently has an average rating of "Moderate Buy" and a consensus target price of $47.37.

Zai Lab Stock Performance

Shares of NASDAQ:ZLAB traded down $1.45 during trading on Wednesday, hitting $34.74. The company's stock had a trading volume of 759,523 shares, compared to its average volume of 907,643. Zai Lab has a fifty-two week low of $16.01 and a fifty-two week high of $44.34. The stock's 50-day moving average price is $33.46 and its two-hundred day moving average price is $31.07. The company has a market capitalization of $3.83 billion, a PE ratio of -13.95 and a beta of 0.96.

Insider Activity at Zai Lab

In related news, CEO Ying Du sold 5,808 shares of the business's stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $35.89, for a total value of $208,449.12. Following the completion of the sale, the chief executive officer now directly owns 476,046 shares of the company's stock, valued at $17,085,290.94. The trade was a 1.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Yajing Chen sold 924 shares of the business's stock in a transaction dated Friday, April 4th. The shares were sold at an average price of $33.11, for a total value of $30,593.64. Following the completion of the sale, the chief financial officer now directly owns 27,047 shares of the company's stock, valued at approximately $895,526.17. This represents a 3.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 167,365 shares of company stock valued at $5,209,564 over the last three months. 4.96% of the stock is owned by insiders.

Hedge Funds Weigh In On Zai Lab

Several institutional investors have recently made changes to their positions in ZLAB. FMR LLC grew its holdings in shares of Zai Lab by 749.1% during the fourth quarter. FMR LLC now owns 5,475,505 shares of the company's stock valued at $143,403,000 after purchasing an additional 4,830,646 shares during the last quarter. RTW Investments LP bought a new position in shares of Zai Lab during the fourth quarter valued at approximately $65,714,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Zai Lab by 46,222.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,132,201 shares of the company's stock valued at $77,058,000 after purchasing an additional 2,127,598 shares during the last quarter. RA Capital Management L.P. bought a new position in shares of Zai Lab during the fourth quarter valued at approximately $33,917,000. Finally, Principal Financial Group Inc. grew its holdings in shares of Zai Lab by 63.6% during the first quarter. Principal Financial Group Inc. now owns 2,884,810 shares of the company's stock valued at $104,257,000 after purchasing an additional 1,121,856 shares during the last quarter. 41.65% of the stock is owned by institutional investors.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.